Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/add.12273 http://scihub22266oqcxt.onion/10.1111/add.12273 23773319/?report=reader!3797155!23773319     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Addiction 2013 ; 108 (11): 1962-8 Nephropedia Template TP {{tp|p=23773319|t=2013. Sensitivity and specificity of a procedure for early human screening of novel smoking cessation medications |pdf=|usr=}}{{23773319}} gab.com Text Sensitivity and specificity of a procedure for early human screening of novel smoking cessation medications JO: Addiction http://www.kidney.de/pget.php?&tw=1&pmid=23773319 #FOAvip BACKGROUND AND AIM: It is important to find economical methods in early Phase 2 studies to screen drugs potentially useful to aid smoking cessation. A method has been developed that detects efficacy of varenicline and nicotine patch. This study aimed to evaluate whether the method would detect the efficacy of bupropion and identify correctly the lack of efficacy of modafinil. DESIGN: Using a within-subject double cross-over design, smokers attempted to quit during each treatment, with bupropion (150 mg b.i.d.), modafinil [100 mg twice daily (b.i.d.)] or placebo (double-blind, counterbalanced order). In each of three medication periods, all smoked with no drug on week 1 (baseline or washout), began dose run-up on week 2, and tried to quit every day during week 3. SETTING: A university research center in the United States. PARTICIPANTS: Forty-five adult smokers high in quit interest. MEASUREMENTS: Abstinence was verified daily each quit week by self-report of no smoking over the prior 24 hours and carbon monoxide (CO) < 5 parts per million. FINDINGS: Compared with placebo, bupropion did (F(1,44) = 6.98, P = 0.01), but modafinil did not (F(1,44) = 0.29, P = 0.60), increase the number of abstinent days. Also, bupropion (versus placebo) significantly increased the number of those able to maintain continuous abstinence on all 5 days throughout the quit week (11 versus four), Z = 2.11, P < 0.05, while modafinil did not (six). CONCLUSIONS: Assessing days abstinent during 1 week of use of medication versus placebo in a cross-over design could be a useful early Phase 2 study design for discriminating between medications useful versus not useful in aiding smoking cessation. Twit Text FOAVip Sensitivity and specificity of a procedure for early human screening of novel smoking cessation medications ????Addiction http://www.kidney.de/pget.php?&tw=1&pmid=23773319 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=23773319 #FOAvip English Wikipedia <ref>{{Cite pmid|23773319}}</ref> Sensitivity and specificity of a procedure for early human screening of novel smoking cessation medications #MMPMID23773319 Perkins KA; Lerman C; Karelitz JL; Jao NC; Chengappa KN; Sparks GM Addiction 2013[Nov]; 108 (11): 1962-8 PMID23773319show ga BACKGROUND AND AIM: It is important to find economical methods in early Phase 2 studies to screen drugs potentially useful to aid smoking cessation. A method has been developed that detects efficacy of varenicline and nicotine patch. This study aimed to evaluate whether the method would detect the efficacy of bupropion and identify correctly the lack of efficacy of modafinil. DESIGN: Using a within-subject double cross-over design, smokers attempted to quit during each treatment, with bupropion (150 mg b.i.d.), modafinil [100 mg twice daily (b.i.d.)] or placebo (double-blind, counterbalanced order). In each of three medication periods, all smoked with no drug on week 1 (baseline or washout), began dose run-up on week 2, and tried to quit every day during week 3. SETTING: A university research center in the United States. PARTICIPANTS: Forty-five adult smokers high in quit interest. MEASUREMENTS: Abstinence was verified daily each quit week by self-report of no smoking over the prior 24 hours and carbon monoxide (CO) < 5 parts per million. FINDINGS: Compared with placebo, bupropion did (F(1,44) = 6.98, P = 0.01), but modafinil did not (F(1,44) = 0.29, P = 0.60), increase the number of abstinent days. Also, bupropion (versus placebo) significantly increased the number of those able to maintain continuous abstinence on all 5 days throughout the quit week (11 versus four), Z = 2.11, P < 0.05, while modafinil did not (six). CONCLUSIONS: Assessing days abstinent during 1 week of use of medication versus placebo in a cross-over design could be a useful early Phase 2 study design for discriminating between medications useful versus not useful in aiding smoking cessation. |Adult[MESH] |Benzhydryl Compounds/*therapeutic use[MESH] |Bupropion/*therapeutic use[MESH] |Carbon Monoxide/analysis[MESH] |Cross-Over Studies[MESH] |Dopamine Uptake Inhibitors/*therapeutic use[MESH] |Double-Blind Method[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Mass Screening/methods[MESH] |Middle Aged[MESH] |Modafinil[MESH] |Self Report[MESH] |Sensitivity and Specificity[MESH] |Smoking Cessation/*methods[MESH] |Smoking/*drug therapy[MESH] |Time Factors[MESH] |Treatment Outcome[MESH] |United States[MESH] |Wakefulness-Promoting Agents/*therapeutic use[MESH]Sensitivity and specificity of a procedure for early human screening o(epmc).pdf DeepDyve Pubget Overpricing